Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pathology. 2010 Jun;42(4):384-94. doi: 10.3109/00313021003779145.

Theranostic and prognostic biomarkers: genomic applications in urological malignancies.

Author information

  • 1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. gnetto1@jhmi.edu

Abstract

Compared to other solid tumours such as breast, colon, and lung, the current clinical management of urological malignancies is lagging behind in terms of utilisation of clinically robust molecular tests that can identify patients that are more likely to respond to a given targeted agent, or even those in need of a more aggressive treatment approach based on well-validated molecular prognosticators. Several promising biomarkers for detection, prognosis, and targeted therapeutics are now under evaluation. The following review discusses some of the candidate biomarkers that may soon make their transition into clinically applicable assays in urological oncology patients.

PMID:
20438413
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk